Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Nat Commun. 2022 May 19;13(1):2800. doi: 10.1038/s41467-022-30481-7.
The TP53 gene is mutated in approximately 60% of all colorectal cancer (CRC) cases. Over 20% of all TP53-mutated CRC tumors carry missense mutations at position R175 or R273. Here we report that CRC tumors harboring R273 mutations are more prone to progress to metastatic disease, with decreased survival, than those with R175 mutations. We identify a distinct transcriptional signature orchestrated by p53R273H, implicating activation of oncogenic signaling pathways and predicting worse outcome. These features are shared also with the hotspot mutants p53R248Q and p53R248W. p53R273H selectively promotes rapid CRC cell spreading, migration, invasion and metastasis. The transcriptional output of p53R273H is associated with preferential binding to regulatory elements of R273 signature genes. Thus, different TP53 missense mutations contribute differently to cancer progression. Elucidation of the differential impact of distinct TP53 mutations on disease features may make TP53 mutational information more actionable, holding potential for better precision-based medicine.
TP53 基因在大约 60%的所有结直肠癌(CRC)病例中发生突变。超过 20%的所有 TP53 突变的 CRC 肿瘤在位置 R175 或 R273 携带错义突变。在这里,我们报告说,携带 R273 突变的 CRC 肿瘤比携带 R175 突变的 CRC 肿瘤更容易进展为转移性疾病,生存率降低。我们确定了由 p53R273H 协调的独特转录特征,暗示了致癌信号通路的激活,并预测了更差的结果。这些特征也与热点突变 p53R248Q 和 p53R248W 共享。p53R273H 选择性地促进 CRC 细胞的快速扩散、迁移、侵袭和转移。p53R273H 的转录输出与 R273 特征基因的调节元件的优先结合相关。因此,不同的 TP53 错义突变对癌症进展的贡献不同。阐明不同的 TP53 突变对疾病特征的不同影响可能使 TP53 突变信息更具可操作性,为更好的基于精准医学的治疗提供潜力。